Pages

In this month’s email, I look at two fascinating developments from recent clinical literature – one exploring the link between hot drinks and oesophageal cancer risk, and another highlighting crucial shifts in guidance regarding Jehovah’s Witnesses and blood products. Both provide essential information to help guide our clinical conversations in primary care.

1. Hot drinks and oesophageal cancer risk – thermal injury in the spotlight

While we often associate oesophageal cancer risk with alcohol and smoking, a massive new prospective analysis involving nearly 1 million UK adults from the Million Women Study and UK Biobank provides compelling evidence on the impact of daily hot beverage consumption over a long-term follow-up (averaging 11–14 years).

Key clinical findings:

• Squamous cell carcinoma (SCC) risk: Drinking beverages at a “very hot” versus “warm” temperature was associated with a three-fold higher risk of SCC (relative risk [RR], 3.17; 95% confidence interval [CI], 2.49–4.03).
• Adenocarcinoma risk: There was no association between “very hot” drink temperature and adenocarcinoma (RR, 0.92; 95% CI, 0.76–1.12).
• High frequency: Consuming six or more hot drinks daily versus fewer than six was associated with a 71% increase in SCC risk (RR, 1.71; 95% CI, 1.51–1.94), independent of temperature.
• Confounding controlled: The associations were largely unaffected by smoking or alcohol intake and remained evident in non-smokers and light drinkers.
  

Mechanism and clinical impact: Thermal injury to the oesophageal mucosa is the likely driver promoting carcinogenesis. The authors estimate that roughly 14% of oesophageal SCCs in the UK could be prevented if individuals who prefer “very hot” drinks cooled them to a “hot” or “warm” temperature.

Primary care takeaway: When taking histories or offering lifestyle advice, advising patients – especially those at higher risk – to let their tea or coffee cool slightly before drinking is a simple, actionable recommendation that could lower oesophageal SCC risk.

For more detailed information, see GPnotebook.

2. Updated guidance – blood components and Jehovah’s Witnesses

Navigating blood transfusion consent with patients who are Jehovah’s Witnesses has historically required careful, delicate navigation. Updated international guidance issued by the Governing Body of Jehovah’s Witnesses brings significant changes regarding individual conscience and blood components.

Key guidance and policy changes:

• Refusal of whole blood: Total refusal of whole blood transfusions remains mandatory under religious doctrine.
• Blood components: Accepting or donating separate components (red blood cells, white blood cells, plasma or platelets) is now officially a matter of individual conscience, and patients no longer face excommunication for accepting them.
• Preoperative autologous donation: The updated guidance permits the collection and storage of a patient’s own blood prior to elective procedures for autologous reinfusion.
• UK clinical context: Because UK transfusions almost exclusively use separated components rather than whole blood, this update allows patients who are Jehovah’s Witnesses to accept most routine UK transfusion products if they choose.
  

Clinical and consent protocols for primary and secondary care:

• Avoid assumptions: Never assume a blanket refusal of all blood products or autologous procedures.
• Individual exploration: Ascertain directly from the patient which specific blood components or autologous techniques they choose to accept or refuse.
• Informed decision-making: Ensure patients are aware of the updated guidance and fully understand the clinical implications of their choices.
• Detailed documentation: Clearly record accepted and refused components in medical records, re-verifying consent whenever clinical circumstances change while respecting autonomous decisions.
  

Primary care takeaway: We can no longer assume that a patient who is a Jehovah’s Witness will refuse all blood-based treatments or pre-op donations. Open, individualised consent conversations are crucial, as many patients may now accept routine separated blood components.

For more detailed information, see GPnotebook.

Other highlights in this month’s email include a summary of post-intensive care syndrome, a trial review of TRIUMPH-1 (retatrutide in the treatment of obesity in patients without diabetes) and guidance with respect to choosing medicines in sulfonamide hypersensitivity.

• Jehovah’s Witnesses and blood transfusion: This update summarises the latest guidance relating to the use of whole blood and blood products by Jehovah’s Witnesses. This GPnotebook update provides essential information to support important conversations with our patients who are Jehovah’s Witnesses in primary care.
• TRIUMPH-1 (retatrutide in the treatment of obesity in patients without diabetes): TRIUMPH-1 is the phase 3 trial of retatrutide in obesity. What was the average weight loss achieved with the 12-mg once-weekly dose in this 80-week trial – 20%, 25% or 28%?
• Post-intensive care syndrome: Post-intensive care syndrome primarily affects the patient following critical illness, encompassing new or worsening physical, cognitive or mental health impairments that persist beyond acute hospital discharge. This condition is summarised on GPnotebook.
• Choosing medicines in sulfonamide hypersensitivity: Guidance is summarised on GPnotebook.
• Tavapadon in Parkinson’s disease: Tavapadon is an oral, once-daily, highly selective dopamine D1/D5 receptor partial agonist evaluated for the treatment of Parkinson’s disease. How does the mechanism of action compare with traditional non-ergot dopamine agonists (for example, pramipexole and ropinirole)?
• Oesophageal cancer risk and consumption of hot drinks: The risks of hot drinks and development of oesophageal cancer are summarised on GPnotebook.